course [1]. AML transformation during hypomethylating therapy for CMML is quite common because of the lack of response to the hypomethylating agent and/or of disease progression [3, 7-9]. The present 2 cases did not provide any evidence that hypomethylating therapy is related to leukemic transformation, clonal selection, or evolution into AML. However, what makes these cases unusual is that the evolution into AML occurred within a few days without any prodromal clinical signs or anticipatory hematological features. Although presented with negative prognostic features both patients achieved a good response to the treatment; however, the responses were transient (2 and 7 months, respectively), and the particularly devastating evolution into AML was characterized by a rapid and prominent leukemic spread and a rapidly fatal clinical course. The biological and clinical features of AML transformation in patients who have received hypomethylators is not fully elucidated and understood; hence, further research into this issue is required to optimize the salvage treatment in this very challenging setting.

Pasquale Nicola, Andrea Tendas, Laura Scaramucci, Marco Giovannini, Daniela Piccioni, Paolo de Fabritiis
Hematology Division, S. Eugenio Hospital, Rome, Italy
Correspondence to: Pasquale Nicola
Hematology Division, S. Eugenio Hospital, Piazzale dell’Umanesimo 10, 00144, Rome, Italy
E-mail: pniccola@gmail.com
Received on Sep. 10, 2013; Revised on Nov. 1, 2013; Accepted on Feb. 19, 2014
http://dx.doi.org/10.5045/br.2014.49.1.65

Authors’ Disclosures of Potential Conflicts of Interest
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:610-9.
2. Courville EL, Wu Y, Kourda J, et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol 2013;26:751-61.
3. Breccia M, Voso MT, Alimena G. Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far? Leuk Res 2013;37:204-5.
4. Kim YJ, Jang JH, Kwak JY, Lee JH, Kim HJ. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. Blood Res 2013;48:87-98.
5. Wijermans PW, Rutger B, Baer MR, Slack JL, Saba HI, Lubbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 2008;32:587-91.
6. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840-9.
7. Thorpe M, Montalvao A, Pierdomenico F, Moita F, Almeida A. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res 2012;36:1071-3.
8. Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 2011;117:2690-6.
9. Fianchi L, Criscuolo M, Breccia M, et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacitidine: results of an Italian retrospective study. Leuk Lymphoma 2013;54:658-61.

TO THE EDITOR: Granulocytic sarcoma (GS) or myeloid sarcoma (MS) is an extramedullary tumor comprising myeloblasts or immature myeloid cells. This type of tumor commonly occurs in subperiosteal bone structures of the skull, paranasal sinuses, as well as the sternum, ribs, vertebrae, pelvis, lymph nodes, and skin [1]. GS is frequently mistaken for non-Hodgkin lymphoma (NHL), small round cell tumors (neuroblastoma, rhabdomyosarcoma, Ewing’s sarcoma/primitive neuroectodermal tumor, and medulloblastoma), or undifferentiated carcinoma. The diagnosis is overlooked in about 50% of the cases when immunohistochemistry (IHC) analysis is not performed [2]. The most common diagnosis, suggested in these situations, is NHL [3]. MS may be the first manifestation of AML, preceding it by months or years, or represent the initial manifestation of relapse in previously treated AML in the remission stage [4]. Isolated MS, defined by the absence of a history of leukemia, myelodysplastic syndrome (MDS), or myeloproliferative neoplasm along with a negative bone marrow biopsy has been described in only a few case reports [5].

Here we report a case of a small gut mass that presented with features of intestinal obstruction necessitating exploratory laparotomy and resection anastomosis of a segment of the small gut. The mass was evaluated for lineage differentiation by IHC and the results correlated with clinicopathologic findings as well as cytogentic and molecular studies.

CASE
A 27-year-old woman presented with recurrent, colicky abdominal pain associated with occasional vomiting for 2 months. There was no history of fever, jaundice, hematemesis, or melena. She had been hospitalized several times and treated conservatively. The patient was conscious, alert, oriented, and afebrile, and her vitals were within normal limits. No pallor, edema, jaundice, clubbing, or superficial...

Blood Res 2014;49:65-73.
lymph node enlargement were present. Her abdomen was soft, non-tender, and not distended. Other systemic examinations revealed no abnormality. Contrast enhanced computerized tomography of the abdomen showed a soft tissue mass lesion (Fig. 1) in the left side of the mesentery with adherent small gut loops.

Exploratory laparotomy was performed. There was moderate ascites without liver nodules or peritoneal deposits. There was an 8.0×7.0 cm globular mass with serosal involvement in the ileum, located 40 cm proximal to the ileo-cecal junction causing luminal obstruction and proximal dilata-

tion, with no apparent mucosal involvement and thickening of the adjacent small bowel. The involved ileal segment was resected with a 10 cm proximal and a 5 cm distal margin, and a side-to-side ileo-ileal anastomosis was performed. On gross examination of the specimen, there was a tumor, 6 cm in diameter, extending outwards into the mesentery and protruding into the intestinal lumen. The cut surface was grayish and fleshy. A total of 10 tiny lymph nodes were seen in the mesentery. Microscopically, the small intestine showed a tumor composed of sheets of atypical large cells with moderate to scanty cytoplasm, a high nucleo-cytoplasmic ratio, and occasional prominent nucleoli. A fair number of eosinophils were also observed (Fig. 2, 3). The tumor cells infiltrated the muscle coat of the intestine and extended up to the serosa. A morphological diagnosis of high grade NHL, large cell type vs. granulocytic sarcoma were differential diagnoses. The surgical resection margins or the lymph nodes were not involved. On IHC analysis, the tumor cells were positive for the leukocyte common antigen, CD117, CD34, myeloperoxidase (MPO), and CD43 and negative for CD20, CD3, CD5, CD10, and CD23. Thus, a final diagnosis of GS (MS) of the small gut was made. A peripheral blood smear showed apparently normal WBC counts with normal differential and platelet counts. Bone marrow aspiration showed normocellular marrow with tri-lineage differentiation. Blast counts were not increased. Conventional cytogenetics showed a normal 46, XX chromosomal pattern. Subsequently, the marrow material was assessed for the presence of common translocations by multiplex RT-PCR and inv(16)(p13q22); CBFB-MYH11 was detected.

In this case, the bone marrow did not show any morpho-
logical involvement; however, the detection of the molecular marker of inv(16)(p13q22) fulfills the criteria of AML diagnosis as defined by the World Health Organization in 2008 [1]. Routine biochemical parameters including serum potassium, calcium, phosphorus, and magnesium were within the reference ranges. Viral markers were negative. After proper counseling, the patient was treated with standard "3+7" daunomycin and cytarabine as remission induction followed by 3 cycles of consolidation therapy with high dose cytarabine [6]. The clinical course of the patient was uneventful during chemotherapy except for 2 occasions of febrile neutropenia, which were managed successfully by antimicrobials. Post consolidation, inv(16)(p13q22) was negative from bone marrow. Post chemotherapy, she is on regular follow up and doing well.

**DISCUSSION**

In the absence of a clinical history of leukemia, a diagnosis of MS can be difficult, despite efforts to establish a tissue diagnosis. MS can often be misdiagnosed, most typically as NHL, in up to 46% of patients [7]. Primary MS has been described in virtually every anatomic location, with a particular predilection for the skin, soft tissue, bone, periosteum, and lymph nodes. Gastrointestinal involvement is infrequent [8]. Acute abdominal pain resulting from partial or complete bowel obstruction is the most common clinical presentation. Grossly, the lesions present as polypoid or exophytic masses, regions of wall thickening and/or ulcerations with a high proclivity for mesenteric and peritoneal dissemination [9]. The present patient had a globular mass with serosal involvement in the ileum, located 40 cm proximal to the ileo-cecal junction causing luminal obstruction and proximal dilatation.

Similar to patients with a history of leukemia, the tissue samples should be sent for IHC, flow cytometry, fluorescence in situ hybridization, cytogenetic and molecular analyses. In addition, once the extramedullary mass has been established, bone marrow aspiration and/or biopsy samples should be subjected to similar analyses [6]. IHC is the most practical method for establishing the diagnosis of MS and can be easier than flow cytometry, which requires cells to be in suspension. IHC can also discriminate between myeloid and non-myeloid cells by using monoclonal antibodies against MPO and lysozyme. MPO staining is very often positive with malignant cells of extramedullary tumors, which is a quick way of establishing the diagnosis and ruling out other tumors [10]. Primary GS of the small intestine is an uncommon entity with a unique histopathology mimicking other solid neoplasms, making it a diagnostic challenge [11]. Although the optimal timing and the treatment of isolated MS are not clear, delayed or inadequately systemically treated isolated MS will almost always progress to AML [12]. The time to the development of AML in this setting ranges 5–12 months [13]. Using RT-PCR, gene fusions specific for AML in the bone marrow of patients with isolated MS have been detected, suggesting that marrow involvement might occur early in the process before clinical detection [14]. Very rarely, cases of MS originating from blasts with inv(16) have also been reported, predominantly occurring with intestinal manifestations [15]. According to Bakst et al. [6], after the standard course of remission-induction chemotherapy, similar to that used for AML, each patient should be evaluated individually and assessed according to multiple prognostic factors including age, comorbidities, degree of dissemination, and cytogenetic/molecular abnormalities, when deciding on a post-remission strategy. Moreover, there is no evidence that an approach combining chemotherapy with radiotherapy is superior to aggressive chemotherapy alone. Patients with MS have a predisposition to extramedullary relapses. After treatment, patients with MS are followed up similarly to other AML patients and undergo detailed physical examinations and routine peripheral blood analyses to confirm continued complete remission.

In summary, the present findings suggest that a high index of suspicion is required to prevent misdiagnosis of MS, and sometimes, molecular analysis is essential for decision making especially when the results for conventional cytogenetics are inconclusive.

Prakas Kumar Mandal¹, Tuphan Kanti Dolai²

¹Department of Pathology, I.P.G.M.E&R., ²Department of Hematology, Nilratan Sircar Medical College, Kolkata, India

Correspondence to: Prakas Kumar Mandal
Department of Pathology, I.P.G.M.E&R., Kolkata-700020, WB, India
E-mail: prakas70@gmail.com

Received on Nov. 2, 2013; Revised on Jan. 13, 2014; Accepted on Mar. 4, 2014

http://dx.doi.org/10.5045/br.2014.49.1.66

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Pilieri SA, Orazi A, Falini B. Myeloid sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, 2008:140-1.
2. Audouin J, Comperat E, Le Tourneau A, et al. Myeloid sarcoma: clinical and morphologic criteria useful for diagnosis. Int J Surg Pathol 2003;11:271-82.
3. Menasce LP, Banerjee SS, Beckett E, Harris M. Extra-medullary myeloid tumour (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases. Histopathology 1999;34:391-8.
4. Maeng H, Cheong JW, Lee ST, et al. Isolated extramedullary relapse of acute myelogenous leukaemia as a uterine granulocytic sarcoma in an allogeneic hematopoietic stem cell transplantation recipient. Yonsei Med J 2004;45:330-3.
5. Eshghabadi M, Shojania AM, Carr I. Isolated granulocytic sar-
Pure erythroid leukemia in advanced breast cancer

TO THE EDITOR: Pure erythroid leukemia (PEL) has been defined as a rare, aggressive disease characterized by a neoplastic proliferation of immature cells committed solely to an erythroid lineage with no increase in myeloblasts in the bone marrow (BM) [1-3]. According to the 2008 World Health Organization (WHO) classification [4], PEL is classified as acute myeloid leukemia (AML), not otherwise specified, only when the case does not fit into any other specific categories. PEL is defined by the presence of immature erythroblasts, which should comprise at least 80% of the BM cells, with no evidence of a significant myeloblastic component [2-4]. PEL accounts for about 10% of all AML cases [2], and it has been very rarely reported as a therapy-related AML [5-8]. Moreover, its occurrence has never been reported after exposure to chemotherapy and radiation for breast cancer.

Here, we describe a case of a 64-year-old woman with a long history of heavily treated breast cancer. She was referred for hematological consultation after failure of erythropoietin treatment for anemia. For the past 16 years, the patient had received multiple courses of radiotherapy and several chemotherapeutic and endocrine agents for her breast cancer. The patient was previously diagnosed with left breast cancer (invasive ductal carcinoma) with involvement of the axillary lymph nodes (pT1b, pN1 [1/6], M0, stage IIA). Cancer cells were positive for estrogen receptor (ER) and progesterone receptor (PR); human epidermal growth factor receptor (HER2) was not tested at that time. The patient was treated with surgery (quarantectomy and axillary lymph node dissection) and adjuvant chemotherapy (6 courses of CMF: cyclophosphamide 600 mg/m², methotrexate 40 mg/m², and 5-fluorouracil 600 mg/m²; cycle repeated every 3 weeks) followed by adjuvant tamoxifen (20 mg/day). The first recurrence was observed 4 years later at a distant site, the T12 vertebral. After receiving radiation therapy (39 Gy in 13 fractions) to the dorsolumbar spine (T11-L1), the patient achieved a complete remission; thereafter, monthly zoledronic acid and daily aromatase inhibitor exemestane were given as maintenance therapies. However, a second relapse (nodal involvement in the right axilla) occurred 3 years later (7 years after initial onset) in the form of an invasive triple negative (negative for ER, PR, and HER2) ductal carcinoma. Thereafter, the patient received docetaxel (100 mg/m² every 3 weeks for 6 cycles) along with local radiotherapy (40 Gy in 20 fractions), achieving a complete remission. However, 2 years later (i.e. 9 years after the first diagnosis), a third tumor relapse occurred. The patient presented with liver metastasis, multiple adenopathies (para-aortic), and diffuse bone osteolysis involving the left fourth rib, the T12 vertebra, and the right iliac wing. Thereafter, non-pegylated liposomal doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) was administered for 6 cycles (each cycle every 3 weeks), and a partial response was achieved. Next, to maintain long-term disease control, the patient received a cyclophosphamide-based metronomic regimen of cyclophosphamide and methotrexate (CM; cyclophosphamide 50 mg p.o. daily and methotrexate 2.5 mg p.o. twice daily on days 1 and 4). However, because of further local disease progression, the patient received radiotherapy targeting the newly recurrent hepatic lesions (75 Gy in 3 fractions) and abdominal lymph nodes (45 Gy in 6 fractions). The CM protocol was interrupted because of additional hepatic metastases and other multiple neoplastic localizations; in particular, a pleural mass and effusion in the left hemithorax, and multiple osteolytic lesions involving the left fourth rib, the left acetabulum, and the ipsilateral iliac wing were detected. Thereafter, the patient received additional radiotherapy (20 Gy in 5 fractions) targeting the skeleton and thorax mass. Next, palliative chemotherapy with vinorelbine (60 mg/m², days 1, 8, and 15 every 3 weeks) combined with capecitabine (1,000 mg/m², days 1–14 every 3 weeks) was administered for approximately 6 months.

When the patient came to our medical facility, she had advanced and active disease with pleural effusion, moderate...